Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study

Ayele, Teshale; Jarso, Habtemu; Mamo, Girma

doi:10.1186/s12981-017-0132-4

Cited by 16 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the changes were mainly from EFV to NVP which could be explained by the fact that EFV is not recommended for women who are pregnant. On comparing the backbone,zinovudine based regimens had a higher drug substitution (aHR 2.067, 95% CI: 1.81-2.36) compared to Tenofovir.This concurs with a study conducted by [14] in Ethiopia which concluded that TDF based regimens have more efficacy that AZT based regimens. Another study in Kenya [15] shows that TDF had lower modifications of the ART treatments.Further, a study in South Africa [16] showed that TDF seemed to perform better notably with less drug substitution.…”

Section: Discussionsupporting

confidence: 90%

Modelling Trends of Cd4 Counts for Patients on Antiretroviral Therapy (Art) : After a Change in Who Guidelines in Kenya

Mugo¹,

Shkedy²,

Mwalili³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background In resource-limited settings, changes in CD4 counts constitute an important component in patient monitoring and evaluation of treatment response as these patients do not have access to routine viral load testing. In this study, we quantified trends on CD4 counts in patients on highly active antiretroviral therapy (HAART) in a comprehensive health care clinic in Kenya between 2011 and 2017.We evaluated the rate of change in CD4 cell count in response to antiretroviral treatment. We further assessed factors that influenced time to treatment change focusing on baseline characteristics of the patients and different initial drug regimens used. The study involved 529 naïve HIV patients that had at least two CD4 count measurements for the period. The relationship between CD4 cell count and time was modeled using a semi parametric mixed effects model while the Cox proportional hazards model was used to assess factors associated with the first regimen change. Results The results demonstrated that CD4 counts increased over time and these trends were similar regardless of the treatment regimen used. Males were less likely to have drug regimens switch (adjusted hazard ratio (aHR) 0.5101, 95% CI: 0.1906 -1.3647) compared to females.Tenoforvir (TDF) based regimens had a lower drug substitution (aHR 0.2796, 95% CI: 0.0961-0.8629) compared to Zinovudine (AZT). Conclusion The backbone used was found to be associated with regimen changes among the patients with fewer switches being observed, with the use of TDF when compared to AZT. There was however no significant difference between TDF and AZT in terms of the change in CD4 count over time.

show abstract

Section: Discussionsupporting

confidence: 90%

Modelling Trends of Cd4 Counts for Patients on Antiretroviral Therapy (Art) : After a Change in Who Guidelines in Kenya

Mugo¹,

Shkedy²,

Mwalili³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…e finding from the marginal analysis also indicated that the change in mean CD4+ count is significantly higher in AZT-based regimens. Adult immunologic studies indicated that a linear trend in CD4+ increment at the early phase of therapy is expected and it became flat with minimal CD4+ gain later after 18 th month of treatment course [29]. However, the linear trend of immunologic recovery may indicate our study was ended prematurely.…”

Section: Discussionmentioning

confidence: 86%

Immunologic Response of HIV-Infected Children to Different Regimens of Antiretroviral Therapy: A Retrospective Observational Study

Mega

Usamo

Negera

2020

AIDS Research and Treatment

View full text Add to dashboard Cite

Background. Both abacavir- (ABC-) based and zidovudine- (AZT-) based regimens are widely utilized for managing HIV infection in children. Unfortunately, there is a lack of data regarding their immunological response and associated risk factors in Ethiopia. Methods. A retrospective hospital-based cohort study was conducted on HIV-infected children in Jimma Medical Center (JMC). A total of 179 records were reviewed by including data from November 2015 to April 2017. Data were collected on sociodemographic, clinical characteristics of patients and drug-related variables. Data analysis was done using STATA 13.1. Mixed-effect linear regression was performed to assess the difference in CD4+ changes between groups adjusting for baseline characteristics. The change in predicted CD4 count attributed to each regimen was also assessed by marginal analysis. P<0.05 for slope of the random-effect linear regression was used as an indicator for the presence of association. Result. Of 179 patients, 98 (54.7%) were females. The mean (±SD) duration of follow-up was 939.8 ± 478.3 and 984.92 ± 453.1 days for ABC and AZT groups, respectively. AZT group had a significant CD4+ count gain per visit compared with their ABC counterparts ((β = 20.51, 95% CI [6.37–34.65]), P=0.004) over time. The regimen AZT + 3TC + LPV/r tended to have an excellent predicted CD4+ lymphocyte count change relative to all other regimens, while ABC + 3TC + LPV/r had the least immunologic recovery (margins 338.0 cells/mm3 versus 249.13 cells/mm3 (P<0.001)). Baseline CD4+ lymphocyte count, ART group, WHO clinical stages, and viral load were independent predictors for CD4+ change overtime. Conclusion. AZT-based regimens seem to have better immunological response compared to ABC-based regimens. Immunologic response was described worse in patients with a viral load of >1000copies/ml, low baseline CD4+ count, advanced WHO clinical stages, and ABC-containing regimens. Further study is needed to clarify these aspects.

show abstract

“…Some studies showed that TDF increases immune response more than AZT. A retrospective cohort study conducted by Ayele, Jarso & Mamo (2017) for two years in Ethiopia showed that the TDF regimen had better immune improvements. A prospective study conducted by Badii & Buabeng (2018) in Ghana also showed that patients taking TDF ARVs had a higher CD4 cell increase compared to those using ZDV.…”

Section: Discussionmentioning

confidence: 99%

Nutritional status and other predictors of immune response recovery among HIV-AIDS patients receiving antiretroviral therapy in Dr. Sardjito Hospital, Yogyakarta, Indonesia: a retrospective cohort study

Asturiningtyas¹,

Subronto²,

Kusmayanti³

2020

Mal J Nutr

View full text Add to dashboard Cite

Introduction: Nutritional status and immune response of Human Immunodeficiency Virus-Acquired Immune Deficiency Syndrome (HIV-AIDS) patients are closely connected. There are limited studies assessing the influence of Body Mass Index (BMI) on immune response recovery among HIV patients in Indonesia. This study aimed to identify the BMI and other predictors of immune response recovery among HIV-AIDS patients following two years of Antiretroviral (ARV) therapy. Methods: This research was a retrospective cohort study among HIV-AIDS patients who started ARV therapy from January 2014 to December 2016 at Dr. Sardjito Hospital, Yogyakarta. Data were collected from ARV registry and medical reports. Data were analysed using linear regression. Results: A total of 255 patients were included in the study, with a median BMI of 20.07 kg/m2. Results showed that BMI was not significantly correlated with immune response recovery at the 6th, 12th, 18th, and 24th months of ARV therapy (p>0.05). But, the increase in cluster of differentiation 4 (CD4) cell count was higher in overweight and pre-obese patients than underweight patients, especially in the 18th and 24th months of therapy. Factors related to immune response recovery were the regularity of treatment at the 12th, 18th, and 24th months of ARV therapy, and the use of Tenofovir at 18th-month therapy (p<0.05). Conclusion: Immune response recovery was higher in overweight and pre-obese patients. Using Tenofovir type ARV and doing treatment regularly can increase CD4 cell counts. Underweight patients need to enhance their nutritional status to improve their immune response during ARV therapy.

show abstract

Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study

Cited by 16 publications

References 26 publications

Modelling Trends of Cd4 Counts for Patients on Antiretroviral Therapy (Art) : After a Change in Who Guidelines in Kenya

Modelling Trends of Cd4 Counts for Patients on Antiretroviral Therapy (Art) : After a Change in Who Guidelines in Kenya

Immunologic Response of HIV-Infected Children to Different Regimens of Antiretroviral Therapy: A Retrospective Observational Study

Nutritional status and other predictors of immune response recovery among HIV-AIDS patients receiving antiretroviral therapy in Dr. Sardjito Hospital, Yogyakarta, Indonesia: a retrospective cohort study

Contact Info

Product

Resources

About